Literature DB >> 9661044

Establishment and characterization of a typical primitive neuroectodermal tumor cell line.

H Horiguchi, M Matsui, R Ohtsubo, T Ogata, M Kaneko, M Fujiwara, H Kamma.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661044     DOI: 10.1007/s11626-998-0074-1

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.723


× No keyword cloud information.
  14 in total

1.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.

Authors:  O Delattre; J Zucman; B Plougastel; C Desmaze; T Melot; M Peter; H Kovar; I Joubert; P de Jong; G Rouleau
Journal:  Nature       Date:  1992-09-10       Impact factor: 49.962

2.  Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12).

Authors:  C Turc-Carel; A Aurias; F Mugneret; S Lizard; I Sidaner; C Volk; J P Thiery; S Olschwang; I Philip; M P Berger
Journal:  Cancer Genet Cytogenet       Date:  1988-06

3.  Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.

Authors:  S L Lessnick; B S Braun; C T Denny; W A May
Journal:  Oncogene       Date:  1995-02-02       Impact factor: 9.867

4.  Chromosome translocation in peripheral neuroepithelioma.

Authors:  J Whang-Peng; T J Triche; T Knutsen; J Miser; E C Douglass; M A Israel
Journal:  N Engl J Med       Date:  1984-08-30       Impact factor: 91.245

5.  MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration.

Authors:  I M Ambros; P F Ambros; S Strehl; H Kovar; H Gadner; M Salzer-Kuntschik
Journal:  Cancer       Date:  1991-04-01       Impact factor: 6.860

Review 6.  Primitive neuroectodermal tumor and Ewing's sarcoma.

Authors:  L P Dehner
Journal:  Am J Surg Pathol       Date:  1993-01       Impact factor: 6.394

7.  Characterization of the ets oncogene family member, fli-1.

Authors:  M J Klemsz; R A Maki; T Papayannopoulou; J Moore; R Hromas
Journal:  J Biol Chem       Date:  1993-03-15       Impact factor: 5.157

8.  Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.

Authors:  K Scotlandi; M Serra; M C Manara; S Benini; M Sarti; D Maurici; P L Lollini; P Picci; F Bertoni; N Baldini
Journal:  Hum Pathol       Date:  1996-04       Impact factor: 3.466

9.  The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product.

Authors:  C Gelin; F Aubrit; A Phalipon; B Raynal; S Cole; M Kaczorek; A Bernard
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

10.  The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts.

Authors:  O Delattre; J Zucman; T Melot; X S Garau; J M Zucker; G M Lenoir; P F Ambros; D Sheer; C Turc-Carel; T J Triche
Journal:  N Engl J Med       Date:  1994-08-04       Impact factor: 91.245

View more
  3 in total

1.  Characterization of a human cell line derived from liposarcoma tissue: is the beta subunit of prolyl 4-hydroxylase specific for a fibroblastic phenotype in culture cells?

Authors:  R Ohtsubo; M Matsui; H Horiguchi; T Ogata; M Fujiwara; T Nagasawa; H Kamma
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-04       Impact factor: 2.416

2.  Establishment and partial characterization of a continuous human malignant glioma cell line: NG97.

Authors:  M C Grippo; P F Penteado; E F Carelli; M A Cruz-Höfling; L Verinaud
Journal:  Cell Mol Neurobiol       Date:  2001-08       Impact factor: 5.046

3.  Establishment of a new human glioblastoma multiforme cell line (WJ1) and its partial characterization.

Authors:  Jing Wang; Xiujie Wang; Shu Jiang; Ping Lin; Jie Zhang; Yaying Wu; Zhujuan Xiong; Jing Jing Ren; Hongliang Yang
Journal:  Cell Mol Neurobiol       Date:  2007-08-17       Impact factor: 5.046

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.